Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Hansa Medical initiates pivotal multicenter study in the US with IdeS for treatment of refractory highly sensitized kidney patients

Regulatory information
Hansa Medical AB (publ) today announced that the company sponsored pivotal multicenter study in the US with IdeS in refractory highly sensitized patients is open for recruitment.

The single arm Phase II study will include approximately 20 highly sensitized patients awaiting kidney transplantation, who are refractory to currently available desensitization strategies. The patients in this new study have either failed on previous attempts of desensitization or the currently available methods are considered insufficiently effective.

The study is entitled "A Phase II Study to Evaluate the Efficacy of IdeS (IgG endopeptidase) to Desensitize Transplant Patients with a Positive Crossmatch Test" with the short name Highdes. The primary objective of the study is to assess the efficacy of IdeS in creating a negative crossmatch test. The trial will also evaluate safety, kidney function and immunogenicity during the 6-month follow-up period. The aim is to complete recruitment of approximately 20 patients over a 12-month period. The recruitment of patients has been initiated at Cedars-Sinai Medical Center in Los Angeles.

"The initial evaluation of the results in the ongoing Phase II studies with IdeS in Sweden and the U.S. verifies our strong belief in the potential of IdeS as a safe, fast and highly effective desensitization treatment. We are excited that we have initiated a fully Hansa Medical sponsored US study with the ambition to recruit patients in immediate need of desensitization”, commented Göran Arvidson, President and CEO of Hansa Medical AB.

Study results could potentially form the basis for filing a Biologics License Application, i.e. an application to the US Food and Drug Administration (FDA) for authorization to commercialize IdeS in the US.

Hansa Medical is currently evaluating the possibility to add European sites to this now initiated study in order to support the regulatory process at the European Medicines Agency, EMA, for marketing authorization of IdeS in the European market.

This study was cleared by the FDA in April 2016. More information about this trial in refractory highly sensitized patients is available at under the identifier NCT02790437.

The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the contact person below on July 19, 2016 at 08.30 CET